Italy
· Delayed Price · Currency is EUR Orion Oyj Company Description
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally.
The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid arthritis and cancer; and Dexdor, Precedex, and Dexmedetomidine products for human use.
It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.
In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other companies.
It has discovery service and commercial license agreement with Invenra to develop bispecific antibody cancer therapeutics; and collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics.
Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.
| Country | Finland |
| Founded | 1917 |
| Industry | Pharmaceutical Preparations |
| Employees | 3,880 |
| CEO | Liisa Hurme |
Contact Details
Address: Orionintie 1A Espo, 02200 Finland | |
| Phone | 358 10 4261 |
| Website | orionpharma.com |
Stock Details
| Ticker Symbol | 1ORNBV |
| Exchange | Borsa Italiana |
| Share Class | Class B Shares |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Liisa Hurme | Chief Executive Officer |
| Rene Lindell | Chief Financial Officer |
| Juhani Kankaanpaa | Chief Operating Officer |
| Tuukka Hirvonen | Head of Investor Relations |